CA3168571A1 - Production de proteine recombinante soluble - Google Patents
Production de proteine recombinante soluble Download PDFInfo
- Publication number
- CA3168571A1 CA3168571A1 CA3168571A CA3168571A CA3168571A1 CA 3168571 A1 CA3168571 A1 CA 3168571A1 CA 3168571 A CA3168571 A CA 3168571A CA 3168571 A CA3168571 A CA 3168571A CA 3168571 A1 CA3168571 A1 CA 3168571A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- protein
- recombinant cell
- peptide
- methionine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title description 59
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title description 59
- 238000004519 manufacturing process Methods 0.000 title description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 235
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 154
- 210000004027 cell Anatomy 0.000 claims abstract description 125
- 229930182817 methionine Natural products 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 75
- 230000014509 gene expression Effects 0.000 claims abstract description 69
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 25
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 25
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 84
- 230000001939 inductive effect Effects 0.000 claims description 70
- 241000588724 Escherichia coli Species 0.000 claims description 66
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims description 65
- 108091005804 Peptidases Proteins 0.000 claims description 54
- 101150077538 gor gene Proteins 0.000 claims description 50
- 102000004190 Enzymes Human genes 0.000 claims description 39
- 108090000790 Enzymes Proteins 0.000 claims description 39
- 101710167005 Thiol:disulfide interchange protein DsbD Proteins 0.000 claims description 37
- 102000035195 Peptidases Human genes 0.000 claims description 35
- 230000002829 reductive effect Effects 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 27
- 239000011347 resin Substances 0.000 claims description 24
- 229920005989 resin Polymers 0.000 claims description 24
- 230000004048 modification Effects 0.000 claims description 21
- 238000012986 modification Methods 0.000 claims description 21
- 235000019833 protease Nutrition 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 13
- 229940118376 tetanus toxin Drugs 0.000 claims description 13
- 229960000814 tetanus toxoid Drugs 0.000 claims description 12
- 150000004676 glycans Chemical class 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- 230000001590 oxidative effect Effects 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 108091081024 Start codon Proteins 0.000 claims description 8
- 238000013519 translation Methods 0.000 claims description 8
- 239000000411 inducer Substances 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 241000193468 Clostridium perfringens Species 0.000 claims description 5
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 5
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 5
- 108010040721 Flagellin Proteins 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 101800003755 Tetanus toxin heavy chain Proteins 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 4
- 108010063907 Glutathione Reductase Proteins 0.000 claims description 4
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims description 4
- 101710114386 Insulin-like protein Proteins 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 101710188053 Protein D Proteins 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 101710132893 Resolvase Proteins 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 108010087851 prorelaxin Proteins 0.000 claims description 4
- 241001529572 Chaceon affinis Species 0.000 claims description 3
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 claims description 3
- 239000000683 Pro-Opiomelanocortin Substances 0.000 claims description 3
- 101800003414 Pro-elastase Proteins 0.000 claims description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 3
- 108010076181 Proinsulin Proteins 0.000 claims description 3
- 108010040806 Prolipase Proteins 0.000 claims description 3
- 108010094028 Prothrombin Proteins 0.000 claims description 3
- 102100027378 Prothrombin Human genes 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 229940039716 prothrombin Drugs 0.000 claims description 3
- 241000588807 Bordetella Species 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 101710182223 Toxin B Proteins 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 14
- 238000003776 cleavage reaction Methods 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 10
- 230000007017 scission Effects 0.000 abstract description 10
- 238000000746 purification Methods 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000004075 alteration Effects 0.000 abstract description 2
- 230000012846 protein folding Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 126
- 101150112095 map gene Proteins 0.000 description 44
- 238000003780 insertion Methods 0.000 description 31
- 230000037431 insertion Effects 0.000 description 31
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 13
- 108010091086 Recombinases Proteins 0.000 description 12
- 102000018120 Recombinases Human genes 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000009448 modified atmosphere packaging Methods 0.000 description 10
- 235000019837 monoammonium phosphate Nutrition 0.000 description 10
- 108091033409 CRISPR Proteins 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000001322 periplasm Anatomy 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 4
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 101150055766 cat gene Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108010060123 Conjugate Vaccines Proteins 0.000 description 3
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 3
- 101000969594 Homo sapiens Modulator of apoptosis 1 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102100021440 Modulator of apoptosis 1 Human genes 0.000 description 3
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 3
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 description 3
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 229940031670 conjugate vaccine Drugs 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- -1 diphtheria toxoid Proteins 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101500028620 Homo sapiens Motilin-associated peptide Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 210000002504 synaptic vesicle Anatomy 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 1
- 108010083493 Cysteine lyase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101150085950 IL10 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102100027612 Kallikrein-11 Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 101150011585 MAT gene Proteins 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102220513293 Protein VAC14 homolog_G52E_mutation Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 101000980867 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Curved DNA-binding protein Proteins 0.000 description 1
- 101000982319 Shallot virus X Uncharacterized ORF4 protein Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000006384 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Human genes 0.000 description 1
- 108010019040 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Proteins 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108030001722 Tentoxilysin Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710152431 Trypsin-like protease Proteins 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010844 nanoflow liquid chromatography Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108010039893 pacifastin Proteins 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
- C12Y108/01007—Glutathione-disulfide reductase (1.8.1.7), i.e. glutathione reductase (NADPH)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
- C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/11—Aminopeptidases (3.4.11)
- C12Y304/11018—Methionyl aminopeptidase (3.4.11.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
L'invention concerne des procédés et des compositions pour l'expression et la purification de produits tels que des peptides et des protéines dans des micro-organismes. En particulier, des pré-produits sont exprimés par recombinaison, le cytoplasme du micro-organisme modifiant les pré-produits exprimés pour produire des produits sous une forme active/finale ou autrement souhaitable. Des modifications associées à l'expression d'un produit recombinant souhaité comprennent le décalage de l'état redox du cytoplasme pour permettre un repliement correct des protéines, le clivage site-dirigé de pré-protéines pour activer la protéine, le clivage site-dirigé d'une méthionine indésirable à partir de l'extrémité N de la protéine, et/ou une ou plusieurs ligations pour former des configurations souhaitées des protéines, le tout dans la même cellule.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062990083P | 2020-03-16 | 2020-03-16 | |
US16/819,775 US11060123B2 (en) | 2014-01-31 | 2020-03-16 | Production of soluble recombinant protein without n-terminal methionine |
US62/990,083 | 2020-03-16 | ||
US16/819,775 | 2020-03-16 | ||
US202163152954P | 2021-02-24 | 2021-02-24 | |
US63/152,954 | 2021-02-24 | ||
PCT/US2021/022126 WO2021188379A2 (fr) | 2020-03-16 | 2021-03-12 | Production de protéine recombinante soluble |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3168571A1 true CA3168571A1 (fr) | 2021-09-23 |
Family
ID=77772149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3168571A Pending CA3168571A1 (fr) | 2020-03-16 | 2021-03-12 | Production de proteine recombinante soluble |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4121541A2 (fr) |
JP (1) | JP7449000B2 (fr) |
KR (1) | KR20220154221A (fr) |
CN (1) | CN115867661A (fr) |
AU (1) | AU2021239914A1 (fr) |
CA (1) | CA3168571A1 (fr) |
WO (1) | WO2021188379A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118207191A (zh) * | 2022-12-18 | 2024-06-18 | 山东合成远景生物科技有限公司 | 一种甲硫氨酸氨肽酶突变体、大肠杆菌工程菌及应用 |
CN117603323B (zh) * | 2023-05-16 | 2024-08-16 | 张文康 | 一种肉毒毒素的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071718A (en) * | 1996-11-27 | 2000-06-06 | Abbott Laboratories | Methods of producing a recombinant protein |
US20060286629A1 (en) * | 2003-12-19 | 2006-12-21 | Norby Inga S N | Processing of Peptides and Proteins |
MXPA06006747A (es) * | 2003-12-19 | 2006-08-18 | Novo Nordisk As | Procesamiento de peptidos y proteinas. |
TW201343911A (zh) * | 2012-04-18 | 2013-11-01 | Providence University | 生產成熟型人類酪胺酸酶的大腸桿菌表現系統及其生產方法 |
JP2017510290A (ja) * | 2014-01-31 | 2017-04-13 | フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー | Crm197および関連タンパク質の発現および精製 |
-
2021
- 2021-03-12 KR KR1020227035931A patent/KR20220154221A/ko unknown
- 2021-03-12 JP JP2022555779A patent/JP7449000B2/ja active Active
- 2021-03-12 AU AU2021239914A patent/AU2021239914A1/en active Pending
- 2021-03-12 WO PCT/US2021/022126 patent/WO2021188379A2/fr active Application Filing
- 2021-03-12 CA CA3168571A patent/CA3168571A1/fr active Pending
- 2021-03-12 EP EP21772422.8A patent/EP4121541A2/fr active Pending
- 2021-03-12 CN CN202180021748.8A patent/CN115867661A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4121541A2 (fr) | 2023-01-25 |
WO2021188379A3 (fr) | 2021-10-28 |
WO2021188379A2 (fr) | 2021-09-23 |
JP2023517708A (ja) | 2023-04-26 |
JP7449000B2 (ja) | 2024-03-13 |
AU2021239914A1 (en) | 2022-09-08 |
CN115867661A (zh) | 2023-03-28 |
KR20220154221A (ko) | 2022-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10287330B2 (en) | Methods and compositions relating to CRM197 | |
EP1206554B2 (fr) | Neurotoxines de recombinaison activables | |
US5427927A (en) | Process for the enzymatic cleavage of recombinant proteins using IgA proteases | |
EP2280066A2 (fr) | Fragments recombinants de la neurotoxine de Clostridium | |
HU205386B (en) | Process for expressing cloned lysostaphin gene and for producing dna fragment containing the gene, expression vector and transformed host cell | |
JP7449000B2 (ja) | 可溶性の組換えタンパク質の生成 | |
WO2024113643A1 (fr) | Neurotoxine botulique recombinante, son procédé de préparation et son utilisation | |
US11060123B2 (en) | Production of soluble recombinant protein without n-terminal methionine | |
RU2144957C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА | |
US20230242961A1 (en) | Production of Soluble Recombinant Protein | |
KR102142255B1 (ko) | Crm197 단백질 발현 방법 | |
RU2143492C1 (ru) | Рекомбинантная плазмида, кодирующая гибридный белок - предшественник инсулина человека (варианты), штамм бактерий e.coli - продуцент гибридного белка - предшественника инсулина человека (варианты), способ получения инсулина человека | |
US12104161B2 (en) | Production of soluble recombinant proteins without N-terminal methionine in E-coli | |
RU2144082C1 (ru) | Рекомбинантная плазмида, кодирующая гибридный белок-предшественник инсулина человека (варианты), штамм бактерий e.coli - продуцент гибридного белка-предшественника инсулина человека (варианты) и способ получения инсулина человека | |
KR102643064B1 (ko) | 발현 수준 및 가용성이 증대된 인간 엔테로키나제 융합 단백질 및 그 제조방법 | |
RU2120475C1 (ru) | Способ получения представляющего интерес полипептида, гибридная днк (варианты), слитый белок (варианты) | |
RU2347811C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pET-KSI-Buf2, КОДИРУЮЩАЯ ГИБРИДНЫЙ БЕЛОК, СОДЕРЖАЩИЙ АНТИМИКРОБНЫЙ ПЕПТИД БУФОРИН-2, ШТАММ Escherichia coli BL21(DE3)/pET-KSI-Buf2 - ПРОДУЦЕНТ УКАЗАННОГО БЕЛКА И СПОСОБ ПОЛУЧЕНИЯ АНТИМИКРОБНОГО ПЕПТИДА БУФОРИНА-2 | |
JP3489865B2 (ja) | ヒト成長ホルモンの製造法 | |
WO2021045292A1 (fr) | Procédé d'expression de protéine crm197 | |
RU2077585C1 (ru) | Рекомбинантная плазмидная днк рдти 23, способ получения рекомбинантной плазмидной днк рдти 23 и штамм бактерий escherichia coli, содержащий рекомбинантную плазмидную днк рдти 23 - продуцент слитого белка дтил 2 | |
JP2006320220A (ja) | プロテインa融合ポリペプチドの製造に利用するdna配列、組換え発現ベクター、形質転換体、およびその融合ポリペプチドの製造方法 | |
CN115927263A (zh) | 一种IgA蛋白酶及其制备方法 | |
KR20040031664A (ko) | 클로로히드린 및 하이드록시카르복실산 에스테르 부제가수분해 효소 유전자 | |
JPH03277278A (ja) | シュードモナス・アエルギノーザ由来アルカリプロテアーゼ遺伝子 | |
JP2003038195A (ja) | 融合蛋白質より有用蛋白質を取得する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220818 |
|
EEER | Examination request |
Effective date: 20220818 |
|
EEER | Examination request |
Effective date: 20220818 |
|
EEER | Examination request |
Effective date: 20220818 |
|
EEER | Examination request |
Effective date: 20220818 |
|
EEER | Examination request |
Effective date: 20220818 |
|
EEER | Examination request |
Effective date: 20220818 |
|
EEER | Examination request |
Effective date: 20220818 |